VYNE Therapeutics (VYNE) Expected to Release Earnings on Thursday

VYNE Therapeutics (NASDAQ:VYNE) is projected to issue its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to post earnings of ($0.18) per share and revenue of $0.20 million for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 19, 2026 at 4:00 PM ET.

VYNE Therapeutics (NASDAQ:VYNE) last issued its earnings results on Friday, May 15th. The company reported ($4.00) EPS for the quarter, topping the consensus estimate of ($9.00) by $5.00. VYNE Therapeutics had a negative return on equity of 70.42% and a negative net margin of 4,726.21%.The company had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.20 million.

VYNE Therapeutics Price Performance

Shares of VYNE Therapeutics stock opened at $28.32 on Wednesday. The business has a fifty day simple moving average of $32.81 and a two-hundred day simple moving average of $31.49. VYNE Therapeutics has a 1 year low of $14.03 and a 1 year high of $79.75. The company has a market capitalization of $18.98 million, a price-to-earnings ratio of -74.54 and a beta of 2.00.

VYNE Therapeutics Announces Dividend

The business also recently announced a special dividend, which was paid on Thursday, July 23rd. Stockholders of record on Wednesday, July 22nd were paid a dividend of $19.00 per share.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in VYNE. Jane Street Group LLC acquired a new stake in shares of VYNE Therapeutics during the second quarter worth $206,000. Adage Capital Partners GP L.L.C. grew its stake in shares of VYNE Therapeutics by 87.2% in the second quarter. Adage Capital Partners GP L.L.C. now owns 644,134 shares of the company’s stock valued at $1,063,000 after acquiring an additional 300,000 shares in the last quarter. Boothbay Fund Management LLC acquired a new position in shares of VYNE Therapeutics in the second quarter valued at about $176,000. Two Sigma Investments LP bought a new position in VYNE Therapeutics during the third quarter worth about $74,000. Finally, Shay Capital LLC bought a new position in VYNE Therapeutics during the third quarter worth about $165,000. Institutional investors own 83.78% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of VYNE Therapeutics in a research note on Monday, May 4th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

About VYNE Therapeutics

VYNE Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies for vascular, inflammatory and fibrotic diseases. The company is advancing a pipeline of selective oral inhibitors that modulate key pathways implicated in chronic tissue damage and immune dysregulation. Headquartered in the San Francisco Bay Area, VYNE Therapeutics seeks to address high-unmet-need conditions by leveraging proprietary chemical and biological insights to create differentiated drug candidates.

The company’s lead program, VTX-002, targets the colony-stimulating factor-1 receptor (CSF-1R) pathway, which plays a central role in macrophage proliferation and activation.